GDF15 and breast carcinoma: Our studies are the first to report activation of IGF-1R-FoxM1 as a mechanism of invasion in GDF15-overexpressing breast cancers, providing rationale for preclinical evaluation of treatments that co-target IGF-1R and FoxM1.